The Japan Mobility Show – which brings together major automakers to show off their upcoming vehicles in Tokyo each year – is still a couple of weeks away. Thankfully, we don't have to wait until then ...

HAMAMATSU, Japan, Oct. 15, 2025 /PRNewswire/ -- Yamaha is proud to announce the launch of MODX M, a new line of midrange synthesizers designed to empower working musicians with exceptional sound, ...

Images of a Yamaha WR155R being ridden on the streets of Bengaluru have surfaced online; however, several details suggest that this isn’t an official test mule. Yamaha India does have an event lined ...

Although Yamaha has long been known for building some of the world’s finest motorcycles, its ventures into the car world have been surprisingly limited and often under the radar, like when it helped ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Yamaha WR155 R you see here looks identical to the model sold in Indonesia. It is finished in Yamaha’s iconic Racing Blue paint scheme and has the same rugged, purposeful design. The temporary ...

It's been 24 years already since Japanese bike maker Yamaha introduced the Max sport scooter range to the world, and the hype it created back then shows no sign of slowing down. In fact, it seems to ...

Cruisers, scooters, dirt bikes, and even small adventure motorcycles are all valid choices for first-time riders. But sport naked bikes are also great and one of the most appealing places to start ...

Yamaha has announced the release of the MODX M Series, an updated version of the company's mid-tier MODX+ workstation synth that integrates features from the high-end Montage M, including the AN-X ...

Yamaha is currently working on a new motorcycle for the Indian market, which is the WR155 R. The dual-sport motorcycle has been spotted testing in Bengaluru, hinting at a launch soon, possibly on ...

Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali trial ...